MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-09-2023
Country |
 USA |
IPO year |
2013 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
3.21 M |
Market Cap[1] |
$ 2.12 M |
EBITDA (LTM) |
$ -10.9 M |
P/E (LTM) |
- |
P/S (LTM) |
105.97 |
EPS (LTM) |
-3.21 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market |  France |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.34 | -3.6 % | $ 357 M | Nasdaq Global Select Market |  Britain |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | France |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
Alterity Therapeutics Limited
ATHE
|
$ 3.65 | 1.3 % | $ 8.78 B | Nasdaq Capital Market |  Australia |
 |
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | USA |
 |
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | USA |
 |
Aytu BioScience
AYTU
|
$ 2.57 | -3.38 % | $ 16.1 M | Nasdaq Capital Market | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market |  Canada |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | Canada |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | Germany |
 |
BioNTech SE
BNTX
|
$ 87.73 | -3.89 % | $ 27.2 B | Nasdaq Global Select Market | Germany |
 |
Coherus BioSciences
CHRS
|
$ 1.6 | -4.19 % | $ 187 M | Nasdaq Global Market | USA |
 |
Akari Therapeutics, Plc
AKTX
|
$ 3.51 | -0.99 % | $ 236 B | Nasdaq Capital Market | Britain |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | USA |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
$ 315.02 | -4.64 % | $ 41.3 B | Nasdaq Global Select Market,SPB | USA |
 |
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | USA |
 |
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market | USA |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Burford Capital Limited
BUR
|
$ 4.43 | -0.89 % | $ 728 M | NYSE | Britain |
 |
Atreca
BCEL
|
- | -11.76 % | $ 5.79 M | Nasdaq Global Select Market | USA |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
 |
argenx SE
ARGX
|
$ 750.73 | 0.33 % | $ 25 B | Nasdaq Global Select Market |  Niderland |
 |
Завод ДИОД
DIOD
|
- | - | - | MOEX,SPB | Russia |
 |
Фармсинтез
LIFE
|
- | - | - | MOEX | Russia |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Aptorum Group Limited
APM
|
$ 0.88 | -0.59 % | $ 4.8 M | Nasdaq Global Select Market | China |
 |
Applied Therapeutics
APLT
|
- | - | $ 8.42 M | Nasdaq Global Market,SPB | USA |
 |
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | USA |
 |
Teligent, Inc.
TLGT
|
- | -13.85 % | $ 16.1 M | Nasdaq Global Select Market | USA |
 |
Cerus Corporation
CERS
|
$ 1.84 | -0.81 % | $ 351 M | Nasdaq Global Market | USA |
 |
AbbVie
ABBV
|
$ 202.18 | -2.15 % | $ 358 B | NYSE,SPB | USA |
 |
Aquestive Therapeutics
AQST
|
$ 4.01 | -2.08 % | $ 429 M | Nasdaq Global Market | USA |
 |
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | USA |
 |
Viela Bio, Inc.
VIE
|
- | - | $ 2.91 B | Nasdaq Global Select Market | USA |
 |
AbCellera Biologics
ABCL
|
$ 3.24 | -4.57 % | $ 968 M | Nasdaq Global Select Market | Canada |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 8.17 | -0.61 % | $ 224 M | Nasdaq Global Market,SPB |  Israel |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.